Truist Financial Boosts Labcorp (NYSE:LH) Price Target to $365.00

Labcorp (NYSE:LH) had its target price raised by equities researchers at Truist Financial from $350.00 to $365.00 in a report released on Monday, Marketbeat Ratings reports. The firm currently has a “buy” rating on the medical research company’s stock. Truist Financial’s price target points to a potential upside of 17.50% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Piper Sandler increased their price target on Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Morgan Stanley raised their price objective on Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Mizuho set a $355.00 price objective on Labcorp in a research note on Monday, August 10th. Finally, Robert W. Baird set a $352.00 target price on Labcorp in a research report on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $337.73.

Labcorp Stock Down 3.2%

Shares of NYSE:LH opened at $310.63 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. Labcorp has a 1 year low of $244.52 and a 1 year high of $341.80. The stock has a market capitalization of $25.19 billion, a P/E ratio of 25.69, a PEG ratio of 1.82 and a beta of 0.88. The stock has a 50-day simple moving average of $316.10 and a 200-day simple moving average of $283.62.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. Labcorp’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities analysts forecast that Labcorp will post 18.32 earnings per share for the current year.

Insider Activity

In other Labcorp news, Director Kerrii Anderson sold 3,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the transaction, the director owned 6,563 shares in the company, valued at $2,087,165.26. The trade was a 31.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn Kyle sold 92 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $26,329.48. Following the completion of the transaction, the executive vice president directly owned 3,904 shares of the company’s stock, valued at approximately $1,117,285.76. The trade was a 2.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,919 shares of company stock worth $2,826,593 over the last three months. 0.84% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Labcorp

Several hedge funds and other institutional investors have recently bought and sold shares of the business. REAP Financial Group LLC increased its position in shares of Labcorp by 20.4% in the fourth quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock worth $55,000 after purchasing an additional 37 shares during the last quarter. V Square Quantitative Management LLC lifted its position in Labcorp by 1.7% during the first quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock valued at $645,000 after purchasing an additional 40 shares during the last quarter. Meeder Advisory Services Inc. lifted its position in Labcorp by 4.5% during the first quarter. Meeder Advisory Services Inc. now owns 1,021 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 44 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in Labcorp by 7.6% in the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 668 shares of the medical research company’s stock worth $168,000 after buying an additional 47 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its stake in Labcorp by 3.6% in the 1st quarter. Moss Adams Wealth Advisors LLC now owns 1,364 shares of the medical research company’s stock worth $364,000 after buying an additional 47 shares in the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Seeking Alpha upgraded Labcorp to Buy, citing durable demand for clinical diagnostics, robust second-quarter results, positive operating margins and growth from new test launches. Its diversified biopharma business may also help offset regulatory pressure. Labcorp’s Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts
• Positive Sentiment: Baird raised its price target on Labcorp to $361 from $352 while maintaining an Outperform rating, signaling continued confidence in the company’s earnings outlook. Baird Adjusts Price Target on Labcorp Holdings
• Positive Sentiment: Truist raised its price target to $365 from $350 and kept a Buy rating, reflecting expected upside after Labcorp’s second-quarter earnings beat. Truist Lifts Price Target on Labcorp Holdings
• Neutral Sentiment: Labcorp’s latest quarterly report exceeded expectations, with adjusted earnings of $4.99 per share versus the $4.78 consensus and revenue of $3.73 billion versus $3.71 billion expected. Revenue increased 5.8% year over year, while full-year 2026 EPS guidance remains $18.10-$18.55.
• Negative Sentiment: Medicare has signaled cuts to payment rates for laboratory services. Because government reimbursement is an important part of Labcorp’s business, investors are concerned that the changes could pressure revenue, margins and future earnings. Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts

About Labcorp

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.